CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment
CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…